Table 3 |
|||
|
Association of phenotypes and genotypes with cessation due to side effects |
|||
|
SNP |
Phenotype/Genotype |
Proportion ceased due to side effects (%) |
Hazard Ratio (95% Confidence Interval), P-value* |
|
|
|||
|
CYP2C19 (CYP2C19*2 (rs4244285), CYP2C19*17 (rs12248560)) |
Poor/Intermediate metabolizers |
8/15 (53.3%) |
0.432 (0.237 to 0.790), P = 0.006† |
|
|
|||
|
Extensive metabolizers |
18/39 (46.2%) |
||
|
|
|||
|
Ultra-rapid metabolizers |
5/21 (23.8%) |
||
|
|
|||
|
ABCG2 421C>A (rs2231142) |
AC |
6/14 (42.9%) |
1.297 (0.527 to 3.194), P = 0.572 |
|
|
|||
|
CC |
27/64 (42.2%) |
||
|
|
|||
|
CYP1A2*1F (rs762551) |
AA |
16/38 (42.1%) |
1.021 (0.508 to 2.050), P = 0.954 |
|
|
|||
|
AC +CC |
17/40 (42.5%) |
||
|
|
|||
|
DHODH 19C>A (rs3213422) |
AA |
9/20 (45%) |
1.002 (0.610 to 1.648), P = 0.993† |
|
|
|||
|
AC |
16/39 (41.0%) |
||
|
|
|||
|
CC |
8/19 (42.1%) |
||
|
|
|||
|
All genotypes are in Hardy-Weinberg equilibrium. *after adjustment for dose, continuing triple therapy and positive rheumatoid factor. † Hazard Ratio and P-value represent a linear test for trend. The Hazard Ratio refers to the hazard associated with each incremental change in phenotype. |
|||
|
Wiese et al. Arthritis Research & Therapy 2012 14:R163 doi:10.1186/ar3911 |
|||
